Baltimore, MD Clinical Trials Report — June 2026

For Baltimore residents considering participation in clinical research, June 2026 presents a mix of urgent opportunities and significant new avenues for contributing to medical science. Across Baltimore, MD, a total of 1,441 clinical trials are currently recruiting across 517 research facilities, offering diverse options for patients and healthy volunteers.

Act Now: Trials Closing Soon in Baltimore

A notable number of clinical trials in Baltimore are nearing their enrollment deadlines, making prompt action essential for interested individuals. Within the next 90 days, 94 trials are slated to conclude. This urgency is particularly relevant for healthy volunteers, as 20 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Patients managing specific health conditions also face impending deadlines to join research. Conditions with trials closing soon include:

• Stroke (4 trials)
• Breast cancer (4 trials)
• Opioid use disorder (3 trials)
• Mild cognitive impairment (3 trials)
• Pancreatic cancer (3 trials)
• Prostate cancer (2 trials)
• Amyotrophic lateral sclerosis (2 trials)
• Chronic pain (2 trials)
• Depression (2 trials)
• Chronic pancreatitis (2 trials)

New Research Opportunities Emerge This Month

This month, Baltimore saw the opening of 20 new clinical trials, a slight increase from the 17 trials that launched in May 2026. These new studies bring cutting-edge research to the city, including significant Phase 2 and 3 drug trials from major sponsors.

Several high-profile new trials are now recruiting in Baltimore:

• AstraZeneca is sponsoring a notable Phase 3 study, NCT07667803, "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This global, randomized, double-blind study aims for 4,500 participants to assess the efficacy and safety of elecoglipron compared with placebo, adjunct to diet and exercise.
• Revolution Medicines, Inc. is leading a Phase 3 trial, NCT07621718, "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )." This study seeks 670 participants to evaluate an investigational RAS(ON) inhibitor in combination with chemotherapy.
• Also from AstraZeneca, NCT07652658 is a Phase 2b study, "A Phase IIb Study to Evaluate AZD8965 in Participants With IPF." This trial aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in 359 participants with Idiopathic Pulmonary Fibrosis (IPF).
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)." This long-term study aims to follow 1,400 people with Down syndrome of all ages to better understand their health, development, and everyday experiences.
• The National Institutes of Health Clinical Center (CC) is behind NCT07647549, "Pulmonary Hypertension (PH) Biorepository for Translational Research." This study seeks 1,000 participants to create a repository of blood samples and health information from people with PH.
• PROCEPT BioRobotics is sponsoring NCT07650448, "WATER IV PCa (AS Sub-study)," a multicenter, prospective, randomized clinical trial aiming for 333 participants to evaluate Aquablation therapy in men with localized prostate cancer.

New trials this month are exploring a range of conditions, with the most frequent being HIV (3 trials), pancreatic ductal adenocarcinoma (PDAC) (2 trials), and Down syndrome (1 trial). Drug trials account for the largest share of new studies, with 11 new drug trials, followed by 4 device trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 20 new trials launched this month, 2 are actively seeking healthy volunteers. Across Baltimore, a total of 219 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research. Remember, 20 of these healthy volunteer opportunities are closing within the next 90 days.

Baltimore's Leading Research Institutions

Baltimore is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Johns Hopkins University (154 trials)
• Johns Hopkins Hospital (116 trials)
• Johns Hopkins University/Sidney Kimmel Cancer Center (70 trials)
• University of Maryland (57 trials)
• University of Maryland/Greenebaum Cancer Center (57 trials)
• Sinai Hospital of Baltimore (52 trials)
• University of Maryland Medical Center (49 trials)
• Research Site (43 trials)
• Johns Hopkins University School of Medicine (42 trials)
• Johns Hopkins (34 trials)
• Johns Hopkins School of Medicine (30 trials)
• Kennedy Krieger Institute (27 trials)

These institutions offer a broad spectrum of research, from oncology at Johns Hopkins University/Sidney Kimmel Cancer Center and University of Maryland/Greenebaum Cancer Center, to diverse medical fields at Johns Hopkins University and the University of Maryland medical centers.

Expanding Your Search: Nearby Maryland Cities

While Baltimore offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Maryland. Cities with active trials include Bethesda (9 trials), Rockville (6 trials), Silver Spring (3 trials), Potomac (2 trials), Lutherville-Timonium (2 trials), Pikesville (2 trials), Brooklyn (1 trial), and Columbia (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 20 new trials launched this month, all 20 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial includes children, 1 is female-only, and 1 is male-only. Academic institutions continue to play a vital role in Baltimore's research ecosystem, with Johns Hopkins University (4 trials) and University of Maryland, Baltimore (2 trials) sponsoring a significant number of new studies. Industry sponsors like AstraZeneca (2 trials) and Revolution Medicines, Inc. are also driving important research efforts.

As we move through June, Baltimore's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.